Skip to main content

RNLXY · Renalytix plc · Metrics

Track RNLXY — free
$3.58 +0.03 (+0.70%) At close · Oct 20
Market Cap
$47.43M
Shares
13.25M
Volume · Oct 20 3200 Avg daily vol (3M) 7239

RNLXY metrics

52 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.58
Market cap
$47.43M

Price action

20 metrics
Price change (1W)
+3.8%
Price change (30D)
-10.5%
Price change (3M)
+79.0%
Price change (6M)
+183.7%
Price change (YTD)
-1.1%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
114.2%
Annualized volatility (3M)
—
Beta
-0.1
RSI (14D)
49.7
Price vs SMA 50
+6.4%
Price vs SMA 200
—
Avg volume (3M)
7,239
Relative volume
0.4
Average dollar volume
$21,564

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
13.25M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
20.2×
reciprocal yield 5.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-59.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-05-15

Profitability

9 metrics
Gross margin
12.7%
Operating margin
-1,054.9%
Trailing 12 months
Net margin
-1,191.8%
Gross profit (TTM)
$299,000
Operating profit (TTM)
−$24.81M
Net income (TTM)
−$28.03M
Trailing 12 months
Diluted EPS (TTM)
$-6.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-10.38
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.27

Growth

11 metrics
Revenue growth YoY
+13.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.35M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.5%
Year over year · more shares
Revenue CAGR (3Y)
+15.4%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-584.7%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$24.52M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$909,000
Latest balance sheet
Cash & equivalents
$909,000
Total assets
$4.79M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$24.44M
Capital expenditures (TTM)
$0
R&D (TTM)
$7.42M
SG&A (TTM)
—
Stock compensation (TTM)
$1.44M
R&D / revenue
315.6%
Stock compensation / revenue
61.3%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1811115 CUSIP 75973T200 Visit website Investor relations